πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 980 pharma-relevant US patents (A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 12186306

Methods of treatment for cystic fibrosis

Vertex Pharmaceuticals Incorporated Β· Granted Tue Jan 07 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12173337

Nucleic acid encoding modified membrane type serine protease 1 (MTSP-1) polypeptides and m

Vertex Pharmaceuticals Incorporated Β· Granted Tue Dec 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12173324

Differentiation of pancreatic endocrine cells

Vertex Pharmaceuticals Incorporated Β· Granted Tue Dec 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12168009

Modulators of cystic fibrosis transmembrane conductance regulator

Vertex Pharmaceuticals Incorporated Β· Granted Tue Dec 17 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12161674

CRISPR-CAS9 modified CD34+ human hematopoietic stem and progenitor cells and uses thereof

Vertex Pharmaceuticals Incorporated Β· Granted Tue Dec 10 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12134767

Materials and methods for treatment of hemoglobinopathies

Vertex Pharmaceuticals Incorporated Β· Granted Tue Nov 05 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 31 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12129471

Materials and methods for treatment of human genetic diseases including hemoglobinopathies

Vertex Pharmaceuticals Incorporated Β· Granted Tue Oct 29 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 24 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12121524

DNA-PK inhibitors

Vertex Pharmaceuticals Incorporated Β· Granted Tue Oct 22 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 17 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12116343

Inhibitors of APOL1 and methods of using same

Vertex Pharmaceuticals Incorporated Β· Granted Tue Oct 15 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 10 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12116606

Complement factor I-related compositions and methods

Vertex Pharmaceuticals Incorporated Β· Granted Tue Oct 15 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 10 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12084438

GCN2 inhibitors and uses thereof

Vertex Pharmaceuticals Incorporated Β· Granted Tue Sep 10 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12065432

Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-me

Vertex Pharmaceuticals Incorporated Β· Granted Tue Aug 20 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 15 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12060346

Inhibitors of APOL1 and methods of using same

Vertex Pharmaceuticals Incorporated Β· Granted Tue Aug 13 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 08 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12053531

Materials and methods for treatment of Duchenne Muscular Dystrophy

Vertex Pharmaceuticals Incorporated Β· Granted Tue Aug 06 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12049645

Differentiation of pancreatic endocrine cells

Vertex Pharmaceuticals Incorporated Β· Granted Tue Jul 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12043843

Materials and methods for treatment of hemoglobinopathies

Vertex Pharmaceuticals Incorporated Β· Granted Tue Jul 23 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12031150

Methods, compositions and kits for increasing genome editing efficiency

Vertex Pharmaceuticals Incorporated Β· Granted Tue Jul 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12006516

Differentiation of pancreatic endocrine cells

Vertex Pharmaceuticals Incorporated Β· Granted Tue Jun 11 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 06 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12005127

DNA-PK inhibitors

Vertex Pharmaceuticals Incorporated Β· Granted Tue Jun 11 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 06 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11999971

Stem cell derived islet differentiation

Vertex Pharmaceuticals Incorporated Β· Granted Tue Jun 04 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 30 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11992506

Stem cell derived pancreatic islet differentiation

Vertex Pharmaceuticals Incorporated Β· Granted Tue May 28 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 23 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11980633

Method for treating cancer using a combination of DNA-damaging agents and DNA-PK inhibitor

Vertex Pharmaceuticals Incorporated Β· Granted Tue May 14 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 09 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11951206

Cell housing device

Vertex Pharmaceuticals Incorporated Β· Granted Tue Apr 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11951212

Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance

Vertex Pharmaceuticals Incorporated Β· Granted Tue Apr 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted